Skip to content
Companies

Optimeos Life Sciences

Non-viral nanoparticles for delivering RNA and biologics

Raised to date

$1M

of $2M offered across 1 Form D filing

Still open
$1M
Investors
1
Last filed
Jun 3, 2026

About

Optimeos Life Sciences is a Princeton University spinout developing non-viral nanoparticle drug delivery systems for biologics, peptides, RNA and DNA therapeutics. Its patented Coated Inverse NanoCarrier (CINC) process encapsulates multiple payload types into customizable nanocarriers with encapsulation efficiencies reported above 90 percent, and a companion LINC format makes long-acting microparticle depots. The company runs preclinical programs in hepatic gene replacement for Citrullinemia Type 1, in vivo T cell engineering, and a long-acting GLP-1 depot, and partners with pharmaceutical companies on formulation. It operates out of Princeton Innovation Center BioLabs and is backed by SBIR awards and venture investors including Hatch BioFund.

A modular, immune-silent non-viral nanocarrier platform that can co-encapsulate several payload classes at once (mRNA, siRNA, DNA, ASO, proteins, peptides, adjuvants) and be targeted to specific tissues while avoiding liver clearance, allowing repeat dosing where viral vectors and conventional lipid nanoparticles cannot.

Funding

  • DebtFiled Jun 3, 2026Form D
    $1M/ $2M

Product

CINCs (Coated Inverse NanoCarriers)

Drug delivery platform

A nanoparticle platform for targeted intracellular delivery of mRNA, DNA and other therapeutic cargo, built on a patented inverse-nanocarrier assembly process developed at Princeton.

  • Co-encapsulation of multiple active ingredients including mRNA, siRNA, tRNA, DNA, ASO, proteins, peptides and adjuvants
  • Encapsulation efficiency reported above 90 percent
  • Modular assembly for tissue-specific targeting and avoidance of liver clearance

Built for

Pharmaceutical and biotechnology companies developing RNA, DNA, peptide and biologic therapeutics that need a delivery vehicle

People on file